12:00 AM
 | 
Aug 17, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Soliris eculizumab regulatory update

The EC granted Orphan Drug designation for Alexion's Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS). The humanized...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >